Table 1. Characteristics and demographics of the included studies.
| Author | Year | (+) | (−) | Follow up (month) | Female (%) | Age (years) | Smoker (%) | Adenocarcinoma (%) | Tumor size (cm) | PET (SUV) | I stage (%) | II stage (%) | III stage (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ctDNA | |||||||||||||
| Abbosh et al. | 2017 | 14 | 10 | 25.2 [22.9–31.5] | 33.33 | NG | 95.80 | 66.67 | NG | NG | 41.67 | 41.67 | 16.67 |
| Chaudhuri et al. | 2017 | 19 | 15 | 35.1 [6.9–56] | 32.00 | 66.8 | 88.00 | 49.00 | NG | 17.2 | 19.00 | 17.00 | 64.00 |
| CTCs | |||||||||||||
| Lara et al. | 2016 | 18 | 38 | 16 [3–23] | 10.70 | 67.4 | 94.60 | 44.60 | 3.60 | 13.17 | 46.40 | 39.30 | 14.30 |
| Crosbie et al. | 2016 | 6 | 21 | 22 [1–52] | 46.70 | 67.5 | 100 | 26.70 | 3.97 | 12 | 40.00 | 36.70 | 23.30 |
| Hofman et al. | 2011 | 144 | 66 | 15 [1–28] | 23.00 | 63 | 88.00 | 73.00 | 3.8 | NG | 43.00 | 19.00 | 29.00 |
+, ctDNA or CTCs positive; −, ctDNA or CTCs negative. ctDNA, circulating tumor DNA; CTCs, circulating tumor cells; PET, positron emission tomography; SUV, standard uptake value; NG, not given.